Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice

Weiping Cao, Jin Hyang Kim, Adrian J. Reber, Mary Hoelscher, Jessica A. Belser, Xiuhua Lu, Jacqueline M. Katz, Shivaprakash Gangappa, Martin Plante, David S. Burt, Suryaprakash Sambhara

*Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

GSK Vaccines, Laval, Quebec H7V 3S8, Canada

Article info

Article history:
Received 6 December 2016
Received in revised form 7 April 2017
Accepted 2 May 2017
Available online 9 May 2017

Keywords:
Protollin
H5N1 vaccines
Mucosal immunity
Cell-mediated immunity
Antibody responses
Protective immunity
Mouse model

Abstract

Sporadic, yet frequent human infections with avian H5N1 influenza A viruses continue to pose a potential pandemic threat. Poor immunogenicity of unadjuvanted H5N1 vaccines warrants developing novel adjuvants and formulations as well as alternate delivery systems to improve their immunogenicity and efficacy. Here, we show that Protollin, a nasal adjuvant composed of *Neisseria meningitides* outer membrane proteins non-covalently linked to *Shigella flexneri* 2a lipopolysaccharide, is a potent nasal adjuvant for an inactivated split virion H5N1 clade 1 A/Viet Nam1203/2004 (A/VN/1203/04) vaccine in a mouse model. Protollin-adjuvanted vaccines elicited enhanced serum protective hemagglutination inhibition titers, mucosal IgA responses, and H5N1-specific cell-mediated immunity that resulted in complete protection against a lethal challenge with a homologous virus as well as a heterologous clade 2 virus A/Indonesia/05/2005 (A/IN/05/05). Detailed analysis of adaptive immunity revealed that Protollin increased the frequency of lymphoid- as well as local tissue-resident antibody-secreting cells, local germinal center reaction of B cells, broad-spectrum of CD4 T cell response. Our findings suggest that nasal delivery of H5N1 vaccine with Protollin adjuvant can overcome the poor immunogenicity of H5N1 vaccines, induce both cellular and humoral immune responses, enhance protection against challenge with clade 1 and clade 2 H5N1 viruses and achieve significant antigen dose-sparing.

1. Introduction

The world has already experienced three influenza pandemics in the 20th century in addition to the recent 2009 pandemic caused by swine-origin H1N1 virus, which has taught us how newly emerging pathogens can be a risk to global populations [1]. Highly pathogenic H5N1 avian influenza viruses continue to be prime candidates for the next influenza pandemic, as they have steadily caused fatal infections in the human population [2]. So far, direct human-to-human transmission appears to be infrequent; however, the accumulation of mutations may break this genetic barrier and generate an H5N1 virus that is transmissible among humans potentially causing pandemic. The inherently poor immunogenicity of unadjuvanted H5N1 influenza vaccines warranted efforts to explore novel adjuvants and alternate delivery systems to improve immunogenicity and protective efficacy of H5N1 vaccines.

Intradermal (i.d.), oral and nasal delivery of vaccines represent alternative routes to conventional intramuscular (i.m.) delivery [3]. Unlike i.m. and i.d. routes, oral and nasal deliveries are non-invasive and needle-free that are known to induce mucosal and systemic immune responses [4]. Since degradation of antigens by proteolytic enzymes, poor absorption, need for large doses of antigen, and concerns about tolerance still remain as challenges for oral delivery of non-replicating vaccine antigens [5], the nasal route has become an attractive option for vaccination, particularly against respiratory pathogens as the respiratory tract is equipped with pathogen sensing defense mechanisms, has a large surface area for absorption, and is highly vascularized [6,7]. A live attenuated seasonal influenza vaccine, which is delivered intranasally (LAIV, FluMist®, Fluenz™) (MedImmune AstraZenica) is approved for healthy individuals of 2–49 years of age in the US. However, the absence of correlates of immunity, cold-storage requirement, and potential of genetic recombination with seasonal influenza viruses may limit the use of LAIV as a pre-pandemic influenza vaccine.
Neisseria meningitidis outer membrane proteins (OMPs) non-correlate with protection. Protollin, a nasal adjuvant composed of Neisseria meningitidis outer membrane proteins (OMPs) non-covalently complexed to Shigella flexneri 2a lipopolysaccharide (LPS) activates the innate immune system via activation of TLR2 and TLR4 by OMP and LPS respectively. Protollin has been shown to induce effective systemic as well as mucosal antibody responses in preclinical studies when administered with several viral antigens such as measles, SARS corona virus, RSV, and recombinant plague antigen F1-V [9–13]. Therefore, Protollin represents an attractive adjuvant suitable for nasal delivery of pre-pandemic H5N1 vaccines. In this study, we evaluated the immunogenicity and protection against challenge conferred by Protollin-adjuvanted H5N1 inactivated split vaccine.

2. Methods

2.1. Reagents and formulations

H5N1 Monovalent Influenza split vaccines (A/VN/1203/04 and A/IN/05/05) were provided by GlaxoSmithKline Vaccines (St. Foy, Quebec, Canada). Protollin from GSK Vaccines consists of proteosomes (outer membrane proteins derived from wild-type Neisseria meningitidis group B) noncovalently complexed in approximately a 1:1 ratio with lipopolysaccharide (LPS) isolated from Shigella flexneri serotype 2a. The amounts of Protollin were expressed as μg of LPS and the amount of H5N1 vaccine was expressed as μg of HA.

2.2. Viruses

Two virus strains were made by reverse genetic engineering, HA and NA from clade 1 A/Viet Nam/1203/2004 (A/VN/1203/04) or clade 2 A/Indonesia/05/2005 (A/IN/05/05) and the remaining six gene segments from A/Puerto Rico/8/1934-(PR8). Viruses were propagated in 10-day old embryonated chicken eggs for 48 h. Pooled allantoic fluid was clarified by centrifugation, aliquoted, and stored at –80°C until use.

2.3. Nasal immunization and challenge of mice

Female BALB/c mice (Jackson Laboratory, Bar Harbor, Maine) 6 weeks of age were anesthetized with intraperitoneal injection (i.p.) of 2,2,2-tribromoethanol in tert-amyl alcohol (Avertin; Sigma-Aldrich, St. Louis, MO) before nasal inoculation with 3, 1, or 0.3 μg of H5N1 vaccine, either alone or with 2 μg of Protollin [10,14] in a final volume of 50 μl administered slowly drop by drop at 25 μl per nostril. Both the vaccine antigens and adjuvants were mixed prior to immunization. Mice nasally administered with adjuvant alone were used as negative controls. Four weeks later, mice received a second dose of the same vaccine preparation. One week after boost, 5 mice were euthanized for collection of spleen and bone marrow tissues to assess adaptive immunity. Bronchoalveolar lavages (BAL) and nasal lavages were also performed at the same time by injecting 1.0 ml PBS with protease inhibitors and re-collecting the fluid to measure mucosal antibody response by ELISA. Mice were bled 3 weeks post-primary and again 3 weeks post-boost to measure hemagglutination inhibition (HI) titers using horse red blood cells. Four weeks after boost, 5 mice from each group were challenged with 5 LD50 of A/VN/1203/04 or A/IN/05/05 viruses. Animals were monitored daily for morbidity by changes in body weight and any mouse that lost >25% of pre-infection body weight was euthanized. Animal research was conducted under the guidance of the CDC’s Institutional Animal Care and Use Committee.

2.4. Statistical analysis

Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA). The Student’s t-test was used to analyze differences in antibody isotype between two groups. One-way analysis of variance with Bonferroni post analysis was used to analyze differences among treatments. The Mann-Whitney test was used to determine significance among HI titers. Finally, the Logrank (Mantel-Cox) test was used to compare percent survival among groups of mice. All differences were considered statistically significant when the p-value was <0.05.

3. Results

3.1. Protollin enhanced protective efficacy of H5N1 split vaccine

To investigate the adjuvant effect of Protollin, mice were nasally administered with 3, 1, or 0.3 μg of H5N1 vaccine with or without 2 μg of Protollin using a prime-booster regime and then challenged with homologous A/VN/1203/04 viruses. All mice immunized with 1 or 0.3 μg of H5N1 vaccine alone succumbed to challenge between day 5 and 6 post-challenge, while 40% of mice that received the highest dose of vaccine (3 μg) initially showed significant weight loss but eventually survived challenge (Fig. 1A and B). All mice immunized with vaccine plus Protollin including mice that received the lowest vaccine antigen dose (0.3 μg), survived and no significant weight loss was observed (Fig. 1A and B). These data demonstrate that Protollin significantly enhanced the protective efficacy of H5N1 vaccine.

To test whether the Protollin-mediated protection extended against cross-clade H5N1 virus, H5N1 vaccine-immunized mice were challenged with the clade 2 virus, A/IN/05/05. Mice immunized with either Protollin or vaccine alone (0.3 or 1 μg) succumbed to challenge (Fig. 1C and D). Among the mice immunized with 3 μg vaccine alone, 80% of mice showed 15% weight loss and eventually recovered and survived. However, Protollin-adjuvanted vaccine, even at the lowest vaccine dose (0.3 μg) significantly reduced weight loss and completely protected mice against the lethal challenge (Fig. 1C and D). Therefore, Protollin also enhanced cross-clade protection with significant antigen dose-sparing.

3.2. Protollin enhanced protective antibody responses

Next, we assessed whether the improved protection conferred by Protollin-adjuvanted H5N1 vaccine was due to enhanced antibody titers. Mice were immunized as described in Fig. 1 and sera were collected at 3 weeks following primary immunization (week 3) and booster immunization (week 7) to measured HI titers against a homologous A/VN/1203/04 virus as well as heterologous A/IN/05/05 virus. Mice immunized with unadjuvanted H5N1 vaccine did not induce detectable antibody titers following primary immunization. However, mice immunized with Protollin–adjuvanted H5N1 vaccine (3 μg HA) developed low level of antibody titers even after a single vaccination (data not shown). At week 7, all mice immunized with vaccine plus Protollin developed significantly higher levels of HI titers against both homologues and heterologous viruses (Fig. 2A and C). However, none of the mice immunized with vaccine alone had detectable HI titers against A/VN/1203/04 virus (Fig. 2A) and only a few mice immunized with either 1 or 3 μg HA of unadjuvanted vaccine developed detectable HI titers against A/IN/05/05 virus (Fig. 2C). Furthermore, vaccine...
alone elicited more IgG1 production than IgG2a, whereas Protollin adjuvantation induced a mixed IgG1 and IgG2a response with a clear trend towards a T<sub>H1</sub> response (IgG2a-dominant) (Fig. 2B and D). These results indicate that Protollin significantly enhanced the immunogenicity of H5N1 vaccine and skewed the immune response towards a T<sub>H1</sub> response.

3.3. Protollin increased the frequency of Ag-specific B and T cells

To determine whether Protollin increased the frequency of Ag-specific memory B cells, mice were immunized as described in Fig. 1 and the frequency of H5N1-specific antibody-secreting cells (ASCs) in spleen and bone marrow was examined by ELISPOT assay. As shown in Fig. 3A and B, the frequency of H5N1-specific IgG and IgM ASCs in the spleen increased in mice immunized with unadjuvanted H5N1 vaccine; Protollin significantly increased the frequency of H5N1-specific IgG and IgM ASCs even at the lowest dose (0.3 μg), although Ag-specific IgM ASCs frequency is much lower than that of Ag-specific IgG ASCs. In bone marrow, the frequency of H5N1-specific IgG ASCs was similarly enhanced by the use of Protollin as an adjuvant, while the frequency of IgM ASCs was minimally affected by Protollin (Fig. 3C and D). Together, these data suggest that intranasal administration of H5N1 vaccine with Protollin enhanced the overall frequency of ASCs with significant dose-sparing effect.

Next, the activation of vaccine-specific T cells in spleen was assessed in mice immunized with 3 μg H5N1 vaccine with or without Protollin. For CD4 T cells, while the production of IL-10 and IFNγ was detectable in mice immunized with unadjuvanted vaccine as compared to the Protollin control group, Protollin adjuvantation further increased the IL-10 and IFNγ production significantly (Fig. 3E). On the other hand, IL-17, IL-21, TNFα, and IL-4 production by activated CD4 T cells was comparable between Protollin alone vs. vaccine group; however, co-administration with Protollin and vaccine significantly increased IL-17, TNFα and IL-4 production from CD4 T cells. Vaccine-specific CD8 T cells responses were slightly increased upon Protollin adjuvantation but this increase was not statistically significant (data not shown). In summary, our data suggest that Protollin–adjuvanted H5N1 vaccine enhanced a broad spectrum of the CD4 T cell activation pathways: T<sub>H1</sub> (IFNγ and TNFα), T<sub>H2</sub> (IL-4 and IL-10) and T<sub>H17</sub> (IL-17).

3.4. Protollin enhanced the mucosal antibody responses

Systemic increase in ASC frequency by Protollin prompted us to assess the extent of homing of ASCs back to the local immune induction site. Thus, we measured the H5N1-binding IgA by ELISA 1 week following booster immunization in the fluids from bronchoalveolar (BAL) and nasal lavage from mice that had been immunized as previously described in Fig. 3. The IgA secretion from unadjuvanted H5N1 vaccine antigen–immunized mice was barely detectable both in nasal lavage (Fig. 4A) and BAL (Fig. 4B). In contrast, the mice immunized with H5N1 vaccine antigen plus Protollin produced A/VN/1203/04-specific IgA at a minimum of 25-fold higher than that of mice immunized with the unadjuvanted vaccine. In addition, Protollin significantly enhanced clade 2 A/IN/05/05-specific IgA secretion both in nasal and BAL as compared to vaccine alone (Fig. 4C and D); Secretion of IgG antibodies was also greatly enhanced by Protollin and the reactivity was extended against clade 2, A/IN/05/05 virus (Fig. 5A–D). However, the frequency of IgM ASCs was much lower and minimally affected by Protollin (Fig. 5E–H). These data indicate that nasal administration of Protollin–adjuvanted H5N1 vaccine enhanced local mucosal immunity throughout the respiratory tract.

3.5. Protollin increased the early B cell response in the draining lymph nodes and spleen

Next, the activation status of B cells at peak of the primary response (day 7) was assessed by flow cytometric analysis. Com-
pared to mice immunized with vaccine alone, mice immunized with vaccine plus Protollin had a higher frequency of B cells participating in GC reaction (Fig. 6A), higher overall mean fluorescence intensity of CD80 among GC-participating B cells, and more GC-B cells expressing high level of CD80 (Fig. 6C and D). The plasma cell differentiation was at low level and did not reveal differences among groups (Fig. 6B). Interestingly, Protollin alone recruited B cells into GC reaction and induced activation (Fig. 6A), emphasizing the significant role of innate signaling through TLR2 and TLR4 in B cell activation. Nonetheless, their recruitment to GC reaction and activation did not result in the production of Ag-specific antibodies (Fig. 2). We also measured the frequency of the splenic Ag-specific IgG and IgM during the primary response and found that Protollin adjuvantation significantly increased the early IgG secretion and marginally IgM secretion (Fig. 6E and F). Overall, these data suggest that Protollin recruited more naïve B cells at the early phase of the vaccine response.

4. Discussion

The spread and evolution of highly pathogenic influenza H5N1 virus in birds worldwide and the increasing number of cases of direct transmission to humans leading to fatalities, have raised concern about an imminent H5N1 influenza pandemic [15]. Vaccination is unquestionably one of the most cost-effective public health interventions available to protect against such pandemics. However, currently available unadjuvanted H5N1 vaccines administered by i.m. route are poorly immunogenic. New strategies to improve the immunogenicity of vaccines with adjuvants, novel formulations and alternate delivery methodologies to meet the demands of global populations are still urgently needed. In the current study, we evaluated the use of Protollin–adjuvanted H5N1 vaccine as a nasally delivered, pre-pandemic vaccine in a mouse model.

The mucosal immune system in the respiratory tract plays an important role in prevention of influenza virus infection. The upper respiratory tract is equipped with not only the physical and dynamic barrier of mucus as well as both soluble and membrane bound pathogen sensors but also contains nasopharyngeal-associated lymphoid tissues (NALT) that are enriched in Ag-specific mucosal effector cells as well as innate immune cells [6]. Hence, nasal delivery of antigens triggers local mucosal as well as a systemic immune response, which is crucial against respiratory pathogens including influenza [16]. Nasal delivery of split, inactivated influenza vaccine generally requires a mucosal adjuvant to induce strong protective immune responses [16]. Some mucosal adjuvants containing bacterial toxin derivatives, including Esherichia coli heat labile enterotoxin (LT) have been clinically eval-
Clinical trials with proteosome-adjuvanted either monovalent H1N1 or trivalent inactivated vaccines have shown that proteosome-adjuvanted vaccines are well-tolerated, while inducing significantly higher serum HI and mucosal secretory IgA titers as compared to unadjuvanted vaccines [18–20]. Preclinical studies using Protollin-adjuvanted H3N2 vaccines also showed the similar results [14,21]. Consistent with this, our data showed that Protollin–adjuvanted H5N1 vaccine induced significantly higher levels of mucosal IgA antibodies against A/VN/1203/04 virus both in nasal washes and lung, with considerable dose-sparing effect. The breadth of the mucosal IgA response was extended against clade 2 virus, A/IN/05/05. As a pre-pandemic vaccine formulation, cross-clade immunity is an important and desirable feature, because the current endemic H5N1 viruses continuously evolve in HA antigenicity through antigenic drift and reassortment, thus making it hard to predict which strain will cause a pandemic. Protollin also induced cross-reactive IgG as well as low, yet detectable levels of IgM antibodies. Lung-resident memory B cells as well as the mucosal, secretory IgA and/or IgG antibodies play a crucial role in conferring protection against influenza virus challenge [22,23]. The mice immunized with Protollin–adjuvanted H5N1 vaccine were completely protected against lethal challenge with clade 1 and clade 2 viruses. Therefore, the Protollin–adjuvanted H5N1 represents a novel pre-pandemic vaccine candidate that is efficient in inducing protective mucosal and systemic immunity.

The adjuvant properties of Protollin have been documented in vaccination with various antigens including measles [9], recombinant SARS-spike glycoprotein [10], respiratory syncytial virus (RSV) [11,12], and recombinant plague antigen F1–V [13]. The level of serum IgG response induced by Protollin is generally comparable to that by alum-adjuvanted vaccines and shows a mixed Th1/Th2 response with a Th1 trend (higher IgG2a/IgG1 ratio) as compared to unadjuvanted vaccines [9,10,13]. Consistent with these findings, our data demonstrated that Protollin potentiated the immunogenicity of H5N1 vaccine. After a single vaccination, mice immunized with Protollin–adjuvanted H5N1 vaccine (3 μg) developed detectable levels of serum HI titers. Following booster immunization, Protollin–adjuvanted H5N1 vaccine significantly increased serum HI titers compared to unadjuvanted vaccine, which coincided with complete protection against homologous virus challenge. The breadth of antibody response was also broadened by Protollin-adjuvanted H5N1 vaccine, as they significantly increased serum HI titers against A/IN/05/05 virus compared to the vaccine alone group and fully protected mice against A/IN/05/05 virus challenge.

Protection against influenza virus infection includes antibody-mediated neutralization/blocking of virus and cell-mediated clearance of virus-infected cells. Although the antigen-specific CD8 T cell responses was not significantly enhanced by Protollin adjuvanted vaccination (data not shown), Protollin-adjuvanted vaccines significantly increased the production of cytokines by antigen-specific CD4 T cells: TNFα (IFN-γ, TNFα), IL-4 and IL-17 (IL–17). IFNγ, as a representative cytokine of Th1 response promotes overall microbial killing through enhancing phagocytosis and recruiting mononuclear cells into the site of infection, while favoring the production of IgG2a from B cells [24–26]. On the other hand, IL-4 along with IL-5, shapes the Th2 response and promotes the production of IgG1 isotype [26]. Consistent with the cytokine profiles, the mice immunized with Protollin-adjuvanted H5N1 vaccine showed significantly increased serum HI titers compared to unadjuvanted vaccine, which coincided with complete protection against homologous virus challenge. The breadth of antibody response was also broadened by Protollin-adjuvanted H5N1 vaccine, as they significantly increased serum HI titers against A/IN/05/05 virus compared to the vaccine alone group and fully protected mice against A/IN/05/05 virus challenge.
Fig. 4. Protollin increased the mucosal antibody responses. Balb/c mice (5 mice/group) were nasally administered with H5N1 split virion vaccine antigen (0.3, 1, 3 μg HA) with or without 2 μg Protollin and a month later, booster immunized with the same vaccine formulations. Control mice received Protollin only at both time points. One week after booster immunization, nasal lavage (A) and BAL (B) fluids were collected and A/VN/1203/04-specific IgA antibodies were assessed by ELISA. Cross-reactivity of nasal lavage (C) and BAL (D) fluids were measured against A/IN/05/05 viruses by ELISA. The amount Ag-specific IgA was presented as relative Ag-binding IgA to mouse IgA. The data is representative of 3 independent experiments (4–5 mice per group) and the error bars represent standard error of the mean (SEM). One-way analysis of variance with Bonferroni post analysis was used to analyze differences among treatments.

Fig. 5. Protollin increased the IgG and IgM production at the mucosal surface. Balb/c mice (5 mice/group) were nasally administered with H5N1 split virion vaccine antigen (0.3, 1, 3 μg HA) with or without 2 μg Protollin and a month later, booster immunized with the same vaccine formulations. Control mice received Protollin only at both time points. One week after booster immunization, nasal lavage (A, C, E and G) and BAL fluids (B, D, F and H) were collected and IgG (A–D) and IgM (E–H) antibodies against A/VN/1203/04 (A–B and E–F) and A/IN/05/05 (C–D and G–H) were assessed by ELISA. The relative amount of virus-specific IgG or IgM antibodies were presented. The data is representative of 3 independent experiments (4–5 mice each group) and error bars represent standard error of the mean (SEM). One-way analysis of variance with Bonferroni post analysis was used to analyze differences among treatments.
a mixed IgG1/IgG2a response with higher production of IgG2a than IgG1. IL-17 is typically associated with pathogenesis of inflammatory diseases [27]. However, the protective role of IL-17 for survival against high dose challenge and severe cases has been recently demonstrated [28,29]. Of interesting note, Protollin-adjuvanted H5N1 vaccine elicited a sharp increase in IL-10 production as compared to vaccine alone. IL-10 is an anti-inflammatory cytokine produced by natural CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) as well as antigen-specific CD4⁺ and CD8⁺ effector T cells [30–32]. It remains unclear the source of IL-10 in our study, but regardless, the enhanced IL-10 production indicates the fine balance between effector vs. control mechanisms was achieved by Protollin. Using gene knock-out mice, TLR4 has been shown to be critical for antigen-specific antibody responses in Protollin-adjuvanted RSV vaccine, while MyD88 was required to elicit a balanced Th1/Th2 immune responses. Although TLR2 is required for nanoparticle formation, it is not playing a role in the adjuvanticity of Protollin [33].

In summary, Protollin demonstrated a significant antigen dose-sparing effect. With Protollin-adjuvanted, H5N1 vaccine antigen at the 10-fold lower dose elicited higher serum HI titer, mucosal antibody responses than the highest vaccine antigen dose (3 μg HA/mouse) against both clade 1 and clade 2 H5N1 viruses. These enhanced immune responses culminated in enhanced protection against challenge with lethal doses of H5N1 viruses of either clade 1 or clade 2. Therefore, nasal delivery of Protollin-adjuvanted H5N1 vaccines is a promising approach that merits further development to prepare for a H5N1 pandemic.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the funding agencies.

Author contributions

W.C., J.K., S.S. designed the experiments and interpreted the data; W.C., J.K., A.R. and M.H. did the in vivo experiments; J.B. did the challenge experiment; X.L did the HI assay; W.C., J.K., and S.S. wrote the manuscript. S.G., J.K., M.P. and D.B. edited the manuscript.

Conflicts of interest

DSB and MP were employees of the GSK group of companies at the time of the study, own stock options in GSK and are listed as inventors on patents owned by the GSK group of companies. The remaining authors declare no commercial or financial conflict of interest.

Funding information

Work was supported by the Influenza Division, Centers for Disease Control and Prevention.

Acknowledgements

We thank the members of Influenza Division, Centers for Disease Control and Prevention for providing reagents and constructive comments during the course of this investigation.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2017.05.004.

References

[1] Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Two years after pandemic influenza A/2009/H1N1: What have we learned? Clin Microbiol Rev 2012;25:223–63.
[2] Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472–7.
[3] Kang SM, Song JM, Kim YC. Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines 2012;11:547–60.
[4] Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 2012;11:595–607.
McGhee Jr, Fujihashi K. Inside the mucosal immune system. PLoS Biol 2012;10:e1001397.

Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001;51:21–42.

Jin H, Subbarao K. Live attenuated influenza vaccine. In: Oldstone MBA, Comps RW, editors. Influenza Pathogenesis and Control, vol. II. Springer; 2014. p. 181–204.

Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, et al. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 2003;21:1374–83.

Hu MC, Jones T, Kenney RT, Barnard DL, Burt D, Lowell GH. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine 2007;25:6334–40.

Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ. CS7Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Vaccine 2007;25:3228–32.

Huang Y, Cyr SL, Burt DS, Anderson R. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. J Clin Virol: Off Publ Pan Am Soc Clin Virol 2009;44:287–91.

Jones T, Adamovicz J, Cyr SL, Bolt CR, Bellerose N, Pitt LM, et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 2006;24:1625–32.

Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 2012;19:209–18.

Paterson AP, Tabak LA, Faucci AS, Collins FS, Howard S. Research funding: A framework for decisions about research with HPAl H5N1 viruses. Science 2013;339:1003–7.

Burt D, Mallett C, Plante M, Zimmermann J, Torosiant K, Fries L. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011;10:365–75.

Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl J Med 2004;350:896–903.

Treanor J, Nolan C, D’Brien D, Burt D, Lowell G, Linden J, et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006;24:254–62.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, et al. Safety and immunogenicity of a Proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006;24:1601–8.

Langley JM, Aoki F, Ward BJ, McGee A, Angel JB, Siver G, et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 2011;29:1921–8.

Ann J, Samant M, Rheuame C, Dumas C, Beauville E, Morasse A, et al. Adjuvanted inactivated influenza A/H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine 2014;32:5730–9.

Onodera T, Takahashi Y, Yokoi Y, Ato M, Kodama Y, Hachimura S, et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc Natl Acad Sci USA 2012;109:2485–90.

Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 1984;14:350–6.

Paludan SR. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand J Immunol 1998;48:459–68.

Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787–93.

Boehm U, Klamp T, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1999;15:749–95.

Bermejo-Martin JF, Ortolaza C, Almansa R, Ramirez-Perez V, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009;13:R201.

Mckinnis KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009;182:7353–63.

Almansa R, Socias L, Ramirez P, Martin-Loeches I, Valles J, Loza A, et al. Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Crit Care 2011;15:448.

Sanchez AM, Zhu J, Huang X, Yang Y. The development and function of memory regulatory T cells after acute viral infections. J Immunol 2012;189:2805–14.

Wang SM, Tsai MH, Lei HY, Wang JR, Liu CC. The regulatory T cells in anti-influenza antibody response post influenza vaccination. Hum Vaccines Immunother 2012;8:1243–9.

Sun J, Madan R, Karp CL, Braciale TJ. Effect on T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009;15:277–84.

Cyr SL, Angers I, Guillot L, Stoica-Popescu I, Lussier M, Qureshi S, et al. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine 2009;27:421–30.